Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero

Cancer

Volumn 77, Issue 3, 1996, Pages 507-513

  Boyd, Jeff ^a,b   Takahashi, Hiroyuki ^a,b   Waggoner, Steven E ^c   Jones, Lovell A ^d   Hajek, Richard A ^d   Wharton, J Taylor ^d   Liu, Fu Shing ^b   Fujino, Takafumi ^b   Barrett, J Carl ^b   McLachlan, John A ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

cervical neoplasm; diethylstilbestrol; DNA repair; estrogen; estrogen receptor; mutation; p53; ras; vaginal neoplasm; WT1

Indexed keywords

DIETHYLSTILBESTROL; ESTROGEN RECEPTOR; MICROSATELLITE DNA; PROTEIN P53;

ARTICLE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HORMONAL CARCINOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL RECORD; ONCOGENE H RAS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUNCH BIOPSY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOGENS; DIETHYLSTILBESTROL; FEMALE; GENES, RAS; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS;

EID: 13344260687     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960201)77:3<507::AID-CNCR12>3.0.CO;2-8     Document Type: Article

References (55)

1. Noller KL, Fish CR. Diethylstilbestrol usage: its interesting past, important present, and questionable future. Med Clin North Am 1974;58:793-810.
2. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81.
3. Melnick S, Cole P, Anderson D, Herbst A. Rates and risks of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix: an update. N Engl J Med 1987;316:514-6.
4. Sedlis A, Robboy SJ. Diseases of the vagina. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 3rd edition. New York: Springer-Verlag, 1987:97-140.
5. Robboy SJ, Herbst AL, Scully RE. Clear cell adenocarcinoma of the genital tract in young females: analysis of 37 tumors that persisted or recurred after primary therapy. Cancer 1974;34:606-10.
6. Herbst AL, Norusis MJ, Rosenow PI, Welch WR, Scully RE. An analysis of 346 cases of clear cell adenocarcinoma of the vagina and cervix with emphasis on recurrence and survival. Gynecol Oncol 1979;7:111-22.
7. Newbold RR, McLachlan JA. Vaginal adenosis and adenocarcinoma in mice exposed prenatally or neonatally to diethylstilbestrol. Cancer Res 1982;42:2003-11.
8. Metzler M, McLachlan JA. Peroxidase-mediated oxidation, a possible pathway for metabolic activation of diethylstilbestrol. Biochem Biophys Res Commun 1978;85:874-84.
9. Liehr JG, Randerath K, Randerath E. Target organ-specific covalent DNA damage preceding diethylstilbestrol-induced carcinogenesis. Carcinogenesis 1985;6:1067-9.
10. Tsutsui T, Maizumi H, McLachlan JA, Barrett JC. Aneuploidy induction and cell transformation by diethylstilbestrol: a possible chromosome mechanism in carcinogenesis. Cancer Res 1983;43:3814-21.
11. Tucker RW, Barrett JC. Decreased numbers of spindle and cytoplasmic microtubules in hamster embryo cells treated with diethylstilbestrol. Cancer Res 1986;46:2088-95.
12. Barrett JC. Molecular mechanisms of hormonal carcinogenesis. In: Li JJ, Nandi S, Li SA, editors. Hormonal carcinogenesis. New York: Springer-Verlag, 1992:159-63.
13. Welch WR, Fu YS, Robboy SJ, Herbst AL. Nuclear DNA content of clear cell adenocarcinoma of the vagina and cervix and its relationship to prognosis. Gynecol Oncol 1983;15:230-8.
14. Hajek RA, Van NT, Johnston DA, Jones LA. In vivo induction of increased DNA ploidy of mouse cervicovaginal epithelium by neonatal estrogen treatment. Biol Reprod 1993;49:908-17.
15. Risinger JI, Terry LA, Boyd J. Use of representational difference analysis for the identification of mdm2 oncogene amplification in diethylstilbestrol-induced murine uterine adenocarcinomas. Mol Carcinog 1994;11:13-8.
16. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988;48:246-53.
17. Boyd J, Barrett JC. Genetic and cellular basis of multistep carcinogenesis. Pharmacol Ther 1990;46:469-86.
18. Newbold RA, Bullock BC, McLachlan JA. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res 1990;50:7677-81.
19. Colton T, Greenberg ER, Noller K, Resseguie L, Van Bennekom C, Heeren T, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. JAMA 1993;269:2096-100.
20. Turusov VS, Trukhanova LS, Parfenov YD, Tomatis L. Occurrence of tumours in the descendants of CBA male mice prenatally treated with diethylstilbestrol. Int J Cancer 1992;50:131-5.
21. Forsberg J-G, Halling A. Failure to detect a second-generation effect in female mice after neonatal treatment with an estrogen (diethylstilbestrol). Acta Anat (Basel) 1992;144: 103-6.
22. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
23. Greenblart MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
24. Hastie ND. Dominant-negative mutations in the Wilms tumour (WT1) gene cause Denys-Drash syndrome - proof that a tumour-suppressor gene plays a crucial role in normal genitourinary development. Hum Mol Genet 1992;1:293-5.
25. Lehrer S, Sanchez M, Song HK, Dalton J, Levine E, Savaretti P, et al. Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer. Lancet 1990;335:622-4.
26. Kamik PS, Kulkarni S, Liu X-P, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:349-53.
27. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-61.
28. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-3.
29. Burks RT, Kessis TD, Cho KR, Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogene 1994;9:1163-6.
30. Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-21.
31. Ignar-Trowbridge D, Risinger JI, Dent GA, Kohler MF, Berchuck A, McLachlan JA, et al. Mutations of the Ki-ras oncogene in endometrial carcinoma. Am J Obstet Gynecol 1992;167:227-32.
32. Liu F-S, Kohler MF, Marks JR, Bast RC Jr, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994;83:118-24.
33. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
34. Gessler M, Konig A, Bruns GAP. The genomic organization and expression of the WT1 gene. Genomics 1992;12:807-13.
35. Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in gynecologic cancers. Nat Genet 1994;7:98-102.
36. Ponglikitmongkol M, Green S, Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J 1988;7:3385-8.
37. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:1906-10.
38. Loeb LA. Microsatellite instability, marker of a mutator phenotype in cancer. Cancer Res 1994;54:5059-63.
39. Modrich P. Mismatch repair, genetic stability, and cancer. Science 1994;266:1959-60.
40. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
41. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38.
42. Papadopoulos N, Nicolaides NC, Wei Y-F, Ruben SM, Carter KC, Rosen CA, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-9.
43. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. Mutation in the DNA mismatch repair gene homologue HMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994;368:255-8.
44. Nicolaides NC, Papadopoulos N, Liu B, Wei Y-F, Carter KC, Ruben SM, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80.
45. Liu B, Parsons RE, Hamilton SR, Petersen GM, Lynch HT, Watson P, et al. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res 1994;54:4590-4.
46. Nystrom-Lahti M, Parsons R, Sistonen P, Pylkaanen L, Aaltonen IA, Leach FS, et al. Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am J Hum Genet 1994;55:659-65.
47. Parsons R, Li G-M, Longley MJ, Fang W-H, Papadopoulous N, Jen J, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993;75:1227-36.
48. Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, et al. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem 1994;269:14367-70.
49. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994;54:4308-12.
50. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
51. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993;90:3988-92.
52. Waggoner SE, Anderson SA, Luce MC, Takahashi H, Boyd J. P53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix. Gynecol Oncol. In press, 1996.
53. Wang L, Patel U, Ghosh L, Banerjee S. DNA polymerase β mutations in human colorectal cancer. Cancer Res 1992;52:4824-7.
54. Dobashi Y, Shuin T, Tsuruga H, Uemura H, Torigoe S, Kubota Y. DNA polymerase β gene mutation in human prostate cancer. Cancer Res 1994;54:2827-9.
55. da Costa LT, Liu B, el-Deiry WS, Hamilton SR, Kinzler KW, Vogelstein B. Polymerase δ variants in RER colorectal tumours. Nat Genet 1995;9:10-1.